Clinical trial
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk…
NCT00324220 · Mirati Therapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT00324220 |
|---|---|
| Title | A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia |
| Official title | A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome or Acute Myelogenous Leukemia |
| Lead sponsor | Mirati Therapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndrome, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | MGCD0103 |
| Enrollment | 66 |
| Start date | Jan 1, 2006 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | May 10, 2006 |
| Last update posted | Jul 1, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: